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Abstract 
Background: Clinical ovulation induction induces blood estrogen (E2) in excess of physiological levels, which can 
hinder uterine receptivity. In contrast, progesterone produces the opposite clinical effect, suggesting that it might 
be capable of recovering the lost receptivity resulting from exposure to high estrogen levels. Integrins are the most 
widely used biological markers for monitoring uterine conditions. We studied progesterone-induced changes in inte-
grin β expression patterns as biomarkers for changes in uterine receptivity in response to increased estrogen levels.
Methods: Endometrial biopsy samples from patients were screened for their estrogen (E2) and progesterone (P4) 
content and expressing levels of integrin β1 and β3. Uterine receptivity was evaluated using human endometrial 
adenocarcinoma cells in an embryo attachment model. The respective and concatenated effects of embryo attach-
ment and changes in the integrin β1 and β3 expression patterns on the adenocarcinoma cell plasma membranes in 
response to 100 nM concentrations of E2 and P4 were evaluated.
Results: Increased blood E2 concentrations were associated with significantly decreased the levels of integrin β3 
expression in uterine biopsy samples. In vitro experiments revealed that a 100 nM E2 concentration inhibited the dis-
tribution of integrin β3 on the plasma membranes of human endometrial adenocarcinoma cells used in the embryo 
attachment model, and resulted in decreased rates of embryo attachment. In contrast, P4 enhanced the expression of 
integrin β1 and promoted its distribution on the plasma membranes. Furthermore, P4 recovered the embryo attach-
ment efficiency that was lost by exposure to 100 nM E2.
Conclusions: Blood E2 and P4 levels and integrin β3 and β1 expression levels in uterine biopsy samples should be 
considered as biomarkers for evaluating uterine receptivity and determining the optimal time for embryo transfer.
Trial registration Trial number: ChiCTR-TRC-13003777; Name of registry: Chinese Clinical Trial Registry; Date of registra-
tion: 4 September 2013; Date of enrollment of the first study participant: 15 October 2013
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Background
Assisted reproduction techniques such as ovulation 
induction, in vitro fertilization (IVF), and embryo trans-
fer (ET) have enabled patients to overcome a variety of 
human infertility disorders. However, the implantation 
rates for most IVF or ET programs remain low, even when 
apparently healthy embryos are used [1]. Differentiation 
of the uterus to a receptive state, as well as the associa-
tion between blastocysts and the uterine luminal epithe-
lium play determinant roles in the embryo implantation 
process [2–4]. In humans, the uterus becomes “recep-
tive” at an appropriate stage of the menstrual cycle, ena-
bling the blastocysts to attach. This so-called “receptive 
window” is initially dependent on the balance between 
estrogen and progesterone levels. Studies in animal mod-
els have shown that estrogen is essential for prepara-
tion of the progesterone (P4)-primed uterus to become 
receptive [2, 5]; however, the exact mechanism by which 
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poorly understood. Due to the potential clinical impor-
tance of the balance between estrogen and P4, it is rea-
sonable to perform a comprehensive study exploring how 
the estrogen-P4 interaction assists in establishing uterine 
receptivity.
Implantation is viewed as a “receptor-mediated” phe-
nomenon [6]; and from that perspective, it is not sur-
prising that extracellular matrix (ECM) ligands play 
fundamental roles in cell–cell interactions that occur 
during implantation [7]. ECM and its receptors mod-
ulate numerous key physiological activities in cells, 
including those related to embryogenesis and fetal 
development [8]. Integrin proteins comprise one major 
class of ECM receptors, and participate in cell–cell and 
cell-substratum interactions. Members of the integrin 
family are transmembrane glycoproteins that are pre-
sent on the plasma membrane and are formed by non-
covalent associations between α and β subunits. Each 
subunit consists of an extracellular domain, an intracel-
lular domain, and a transmembrane region. The specific 
participation of integrins in implantation has early been 
demonstrated: based on the previous studies, members 
of integrins play key roles in the signaling [9], mainte-
nance of epithelial polarity [10], and developmental 
progression of placental cytotrophoblast to an invasive 
phenotype [11]. While human uterine epithelium and 
glandular epithelial cells express multiple integrins [8], 
only the secreted integrins α1β1, α4β1 and αvβ3 display 
periodicity. Integrin β1 is constitutively expressed dur-
ing the menstrual cycle and mouse blastocytes lack of 
integrin β1 subunit fail to implant, which is due to the 
inability to adhere or to invade the subepithelial stroma 
[12]. Integrin β3 is expressed on a weekly basis by epi-
thelial cells in regions of proliferative endometrium 
[13]. Up-regulation of integrin β3 by the blastocyst has 
been proved in co-cultured human endometrial epithe-
lial cells, which might be mediated by the embryonic 
IL-1 system [14]. Indeed, integrins are some of the best 
characterized biomarkers of uterine receptivity, and 
the roles they play in implantation have been widely 
reviewed [15–17].
Based on the above information, it was reasonable for 
us to comprehensively study the mechanism through 
which integrins β1 and β3 took their action in the for-
mation of uterine receptivity which is driven by balance 
transition between estrogen and P4 balance. For such 
purpose, a series of in vivo and in vitro assays were per-
formed in the current study. And with findings outlined 
in the current study, we expected to confirm the potential 
of integrins β1 and β3 as biomarkers for monitoring the 
estrogen-P4 balance during the establishment of uterine 
receptivity and reveal the interaction between estrogen 
and P4 during the process.
Methods
Chemicals, cell cultures, and animals
17-β estradiol (E2, dissolved in ethyl alcohol), progester-
one (P4, dissolved in DMSO), and 2  % gelatin solution 
were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Anti-integrin β1 (CAT. ab52971) and anti-integ-
rin β3 (CAT. ab75872) antibodies were purchased from 
Abcam (Cambridge, UK). FITC labeled anti-integrin β3 
antibody (CAT. 555753) was from BD Bioscience (San 
Jose, CA, USA). Anti-integrin β1-Alexa Fluor® 488 Anti-
body (CAT. FCMAB375A4) was purchased from Milli-
pore (Bedford, MA, USA). The western blotting detection 
reagents were from Amersham (Arlington Heights, IL, 
USA). All other chemicals were purchased from Sigma-
Aldrich. Human endometrial adenocarcinoma cells (Ishi-
kawa) were maintained in DMED/F12 nutrient mixture 
(Life Technologies, Gaithersburg, MD, USA) containing 
10 % fetal bovine serum (FBS), 1 mM sodium pyruvate, 
2 mM l-glutamine, 100 μg/mL streptomycin, and 100 IU/
mL penicillin in an atmosphere of 95 % air and 5 % CO2 
for 48 h prior to hormone treatment and embryo attach-
ment. Female C57BL/6 × DBA/2 mice (aged 8–10 weeks) 
were purchased from Shanghai SIPPR BK Laboratory 
Animal Ltd., and housed in an environmentally con-
trolled facility, with food and water available ad librum.
Patients and clinical interference
When patients underwent in vitro fertilization from 2013 
to 2014 at the Shanghai Jiai Genetic and IVF Institute, 
forty-four patients were enrolled for this study. None of 
them had received any hormone therapy or an intrauter-
ine device (IUD) within 3  months prior to their biopsy 
procedure. Patients who had polycystic ovaries (PCO), 
endometriosis, endometrial polyp or any other uncon-
formable complaints or signs were excluded. The forty-
four patients were randomly assigned to three groups for 
further analysis. Subjects in the control group (n =  13) 
began using the Luteinizing Hormone (LH)-surge test 
paper detection method starting on day 9 of menstrua-
tion, with the day of ovulation defined as D0. These 
patients underwent an endometrial biopsy on D5. The 
remaining 31 patients received 0.05  mg Gonadotropin-
Releasing Hormone (GnRHa) for 14 days, starting on day 
21 of menstruation. Next, follicle-stimulating hormone 
(FSH) was injected to stimulate the secretion of follicles 
until a subsequent injection of human chorionic gonado-
tropin (HCG) (D0). An endometrial biopsy was collected 
on D5. The 31 patients were then randomly assigned to 
two groups on D0. Based on previous studies, an E2 con-
centration of 10  nM was deemed optimal for inducing 
phosphorylation of ERK1/2 and Akt, and that E2 level was 
selected as the grouping criterion in the present study 
[18]. Patients with an E2 level ≤10 nM were assigned to 
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a normal effect group (NE group, n = 13), while patients 
with an E2 level  >10  nM were assigned to an increased 
[E2] group (OP group, n  =  18). Endometrial cells were 
collected from all patients in both groups.
Real time quantitative PCR
For qPCR detection, the total RNA from different sam-
ples was extracted using TRIzol reagent according to the 
manufacturer’s instructions. GAPDH served as a refer-
ence gene. The cDNA templates for integrins β1 and β3 
were created by reverse transcription of RNA using a 
RT-PCR kit (Fermentas; Waltham, MA, USA). The 20 μL 
reaction mixture consisted of 10 μL of SYS BR Primix Ex 
Taq 2 solution, 0.5  μL of each primer (integrin β1, for-
ward primer: ATGTGTCAGACCTGCCTTGG, reverse 
primer: GGGACACAGGATCAGGTTGG; integrin β3, 
forward primer: GGCAAGTGTGAATGTGGCAG, 
reverse primer: GACTCAATCTCGTCACGGCA; 
GAPDH forward primer: 5′-TATGATGATATCAA 
GAGGGTAGT, reverse primer, 5′-TGTATCCAAACT 
CATTGTCATAC-3′), 1  μL of the cDNA template, and 
8  μL of RNase-free H2O. The amplification conditions 
were as follows: a denaturation step performed at 95  °C 
for 10 min, followed by 40 cycles at 95 °C for 15 s, 60 °C 
for 1 min, and 72 °C for 30 s. The relative integrin β1 and 
β3 expression levels were calculated using Data Assist 
Software version 3.0 (Applied Biosystems/Life Technolo-
gies; Carlsbad, CA, USA) and the 2−∆∆ct method.
Treatment of Ishikawa cells with E2 and P4
Ishikawa cells were seeded into six-well plates (2 ×  105 
cells/well) and incubated with culture medium for 
24  h. Following culture, the medium was aspirated and 
replaced with phenol-red free medium supplemented 
with 2.5 % CS-FBS. Forty-eight hours later, the cells were 
treated with E2 (0, 0.1, 1, 10 and 100 nM), P4 (0, 0.1, 1, 
10 and 100 nM) or E2 plus P4 (0–0, 100–0, 100–10 and 
100–100 nM, respectively) for 16 or 48 h. Each treatment 
group consisted of three replicates.
Western blotting assay
Ishikawa cells which had received the different treat-
ments were scraped from the six-well plates and lysed 
with RIPA lysing buffer (Beyotime; Nantong, China) con-
taining 1  mM PMSF and a protease inhibitor cocktail 
(Beyotime). The lysed cells from each treatment group 
were centrifuged at 16,000g for 20  min, and the super-
natant fractions were collected. Next, a 20 μg sample of 
supernatant protein was separated by 8  % SDS-PAGE, 
and then semi-dry blotted onto PVDF (polyvinylidene 
fluoride) membranes (Millipore, Bedford, MA, USA). 
After being blocked for 2  h with TBST containing 
5  % non-fat dry milk, the membranes were incubated 
overnight at 4 °C with a primary rabbit monoclonal anti-
body to integrin β1 (1:5000) or integrin β3 (1:5000); after 
which, they were incubated with the HRP-labeled sec-
ondary antibody (1:10,000; Cwbiotech, Beijing, China) for 
1 h at room temperature. HRP-labeled β-actin (1:10,000; 
Sigma-Aldrich) was used as an internal control protein. 
The protein blots were developed using Beyo ECL Plus 
reagent (ThermoFisher Scientific; Waltham, MA, USA), 
and the results were recorded with a gel imaging system. 
The relative expression levels of integrins β1 and β3 in 
the different samples were calculated using a Gel-Pro-
Analyzer (Media Cybernetics; Rockville, MD, USA).
Flow cytometry
The distribution and relative amounts of integrins 
located on the surface of Ishikawa cells were analyzed 
by flow cytometry. After 16 h of hormone treatment, the 
starved Ishikawa cells were scrapped off of their culture 
dishes, washed with PBS, and adjusted to a concentration 
of 1 × 106 cells/mL. Next, an aliquot containing 1 × 106 
cells was labeled with FITC-labeled anti-integrin β3 anti-
body (1:100) or Anti-Integrin β1-Alexa Fluor® 488 Anti-
body (1:50) in the dark for 1  h. After labeling, the cells 
were washed and resuspended in 200 μL of PBS; after 
which, the distribution and amount of integrins on their 
surfaces were analyzed using a BD FACSCanto II system 
(BD Biosciences; Franklin Lakes, NJ, USA).
Ovulation induction and embryo collection
Female C57BL/6 ×  DBA/2 mice were superovulated by 
intraperitoneal injection with 10  IU of pregnant mare 
serum gonadotrophin (PMSG). At 46–48  h post-PMSG 
injection, 10  IU of human chorionic gonadotrophin 
(HCG) was injected; after which, each female mouse was 
housed with male mice overnight. The presence of a vagi-
nal plug the following morning was defined as an indica-
tor of successful mating. After mating, two-cell embryos 
(1.5 dpc) were collected from the oviduct of each mouse 
under a microscope. The flushed embryos were washed 
with M2 medium (Sigma-Aldrich) containing 4  mg/mL 
BSA, and then transferred into a 60 μL drop of KSOM 
medium (Millipore) for further washing. After washing 
in KSOM, the embryos were cultured in a 30 μL drop of 
KSOM covered with mineral oil, and incubated at 37 °C 
in an atmosphere of 5 % CO2 until reaching the blasto-
cyst stage. Only expanded blastocysts (3.5 dpc) with nor-
mal morphology were used in further experiments.
Analysis of embryo attachment
E2 (0, 10 and 100 nM) or E2 and P4 at different concen-
trations (100–1, 100–10 and 100–100 nM) was added to 
starved Ishikawa cells being cultured in gelatin-coated 
12-well plates. Next, based on the total number of 
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blastocytes recovered, five to 15 randomly selected blas-
tocysts (3.5 dpc) were transferred into a hormone-treated 
well and incubated for 48 h; after which, the ability of the 
embryo to attach to the well was determined by micro-
scopic examination using a previously published method 
[19]. Three samples of each treatment group were exam-
ined for attachment.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 5.0 software (GraphPad Software Inc; La Jolla, 
CA, USA) and IBM SPSS Statistics for Windows, Version 
19.0. Armonk, NY: IBM Corp. Data are expressed as the 
mean ±  SE or mean ±  SD. Multiple means were com-
pared using the two-tailed and paired T tests. P  <  0.05 
were considered statistically significant.
Results
Patient demographic information and the effect of HCG 
treatment on E2 and P4 production
The three groups of patients were not significantly dif-
ferent in their conformable complaints, mean age, mean 
Body Mass Index (BMI) value, clinical signs or basal 
levels of E2, P4, LH, and FSH (Table 1; Additional file 1: 
Table S1). The levels of E2 and P4 were dramatically up-
regulated following administration of HCG (Table 2). As 
described in “Methods” section, the patients were divided 
into two groups based on their level of E2. Patients in the 
normal- and increased-E2 groups showed no significant 
difference in their P4 levels.
Inhibition of integrin β1 and β3 expression was associated 
with increased E2 level
It is known that integrin is one major member of extra-
cellular matrix protein to modulate cell migration, cell–
cell junction and embryo implantation. Integrin α1, α4, 
α5, β1 and β3 were reported to express in uterine endo-
metria epithelia cells. We then measured the expres-
sion level of those integrins. There was no significantly 
difference expression level of integrin α1, α4 and α5 in 
all groups (data not shown). As illustrated by the qPCR 
results, there were significant differences between the rel-
ative levels of integrin β1 and β3 expression in the control 
group and high E2 group (P < 0.01; Fig. 1a, b; Additional 
Table 1 Characteristics of the women in natural and stimulated cycles
Values are mean ± SD
BMI body mass index; GN gonadotropin; COH controlled ovarian hyperstimulation
Group COH cycle
Control group (Ctr; n = 13) Normal effect group (NE; n = 13) Over physiological group 
(OP; n = 18)
Age (year) 30.77 ± 1.29 28.54 ± 0.81 28.61 ± 0.69
BMI (kg/m2) 22.56 ± 0.87 21.19 ± 0.84 20.65 ± 0.76
Basal level
 E2 (pM) 126.19 ± 12.52 130.43 ± 13.48 145.58 ± 16.46
 P4 (pM) 0.67 ± 0.10 0.75 ± 0.11 0.49 ± 0.10
 LH (mIU/ml) 4.85 ± 0.54 3.55 ± 0.49 4.35 ± 0.32
 FSH (mIU/ml) 8.19 ± 0.63 6.78 ± 0.48 7.62 ± 0.42
 T (ng/dl) 38.00 ± 3.43 37.38 ± 2.15 36.61 ± 3.01
 PRL (ng/ml) 17.86 ± 3.14 20.21 ± 2.41 16.17 ± 1.90
 GN 22.12 ± 1.14 22.48 ± 1.48
Table 2 The hormon level of the patients at day 5 after HCG injection
Values are mean ± SD, Group NE vs Group OP
** P < 0.01
HCG administration
Normal effect group (NE; n = 13) Over physiological group (OP; n = 18)
E2 (pM) 6545.02 ± 527.64 20,722.12 ± 1426.15**
P4 (pM) 1.15 ± 0.18 1.55 ± 0.27
LH (mIU/ml) 4.75 ± 0.98 2.74 ± 0.63
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file 1: Tables S2, S3); however, there was no significantly 
difference between the expression levels of these two 
indicators in the normal E2 and control groups (Fig. 1c, 
d). These results might be due to the blocking effect of E2 
overexpression on integrin β1 and β3 transcription.
Expression and surface distribution of integrin β3 
on Ishikawa cells was regulated by E2
To verify the regulatory effect of E2 on the expression of 
integrin β1 and β3, Ishikawa cells were exposed to dif-
ferent concentrations of E2; after which, the expression 
and distribution of the two integrins on the cell surface 
were detected. The results showed that contrary to our 
findings with clinical samples, different concentrations 
of E2 had little effect on the expression or distribution of 
integrin β1 on Ishikawa cells. We hypothesize that the E2 
concentrations administered to Ishikawa cells needed to 
be much higher to induce any significant changes in inte-
grin β1 expression and distribution (Fig. 2a–c; Additional 
file  1: Figure S1). In contrast, E2 administration pro-
duced remarkable alterations in the expression level and 
distribution of integrin β3 (Fig.  2d–f; Additional file  1: 
Figure S2). When the concentration of E2 was within a 
normal physiological range (<10 nM), the expression and 
distribution of integrin β3 was positively correlated with 
the concentration of E2; with 10  nM E2 exhibiting the 
most powerful promoting effect. However, when a higher 
than physiological concentration of E2 was administered 
(100  nM), there were dramatic declines in integrin β3 
expression and distribution. Moreover, these declines 
were consistent with results obtained when using clinical 
samples.
The expression and surface distribution of integrin β1 
on Ishikawa cells was regulated by P4
We assessed the effect of P4 on the expression and sur-
face distribution of integrins β1 and β3 in Ishikawa cells. 
Contrary to the effect of E2, administration of P4 had no 
influence on the activity of integrin β3; however, it had a 
positive effect on the production and distribution of inte-
grin β1, even at a concentration of 100 nM (Fig. 3; Addi-
tional file 1: Figure S3, S4).
Fig. 1 Expression levels of integrins β1 and β3 in endometrial cells were negatively associated with E2 levels in clinical samples. a, b Quantitative 
analysis of integrin β1 and β3 mRNA expression levels in the over physiological E2 group (OP). c, d Quantitative analysis of integrin β1 and β3 mRNA 
expression levels in the physiological effect group (NE). Double asterisk indicates significantly different from the control group, P < 0.01; NS not 
significantly different
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Administration of P4 alleviated the negative effect 
of 100 nM E2 on integrin β3
As demonstrated above, when administered at a concen-
tration of 100  nM, E2 decreased the activity of integrin 
β3 in Ishikawa cells (Fig. 2d–f). However, when the cells 
were treated with 100 nM E2 plus different concentration 
of P4, the inhibitory effect of E2 on integrin β3 was elimi-
nated (Fig. 4d–f; Additional file 1: Figure S5). The effects 
of concatenated administration on integrin β1 were 
similar to those obtained by administration of P4 alone 
(Fig. 4a–c; Additional file 1: Figure S6).
P4 treatment increased the E2‑induced reduction 
in implantation rate
A 10 nM E2 concentration increased integrin β3 distribu-
tion on plasma membrane and enhanced embryo attach-
ment when compared with a 0  nM E2 concentration 
(Fig.  5a; P  <  0.01). However, a 100  nM E2 concentration 
reduced integrin β3 distribution on plasma membrane and 
inhibited embryo implantation compared with a10 nM E2 
concentration (Fig. 5; P < 0.01). Treatment with P4 clearly 
ameliorated the negative effect of E2 on implantation in a 
dose-dependent manner, because P4 significantly enhanced 
the integrin β1 expression and distribution on plasma 
membrane (Fig.  4a–c). The difference in implantation 
rates obtained with 100 nM E2 treated cells and 100 nM P4 
treated cells was statistically significant (P < 0.01).
Discussion
Ovulation induction results in an increased [E2] and 
a lower embryo implantation rate. Moreover, E2 and 
P4 production are closely interconnected during the 
menstrual cycle. The respective role and molecular 
mechanism of each ovarian hormone has not been fully 
elucidated. Fortunately, the establishment of prime 
endometrial receptivity can serve as an original model 
in which to study the consequences of a single hormo-
nal alteration on endometrial tissue [20]. In the current 
study, the respective effects of E2 and P4 on the combined 
expression patterns of integrins β1 and β3, which are bio-
markers of uterine receptivity [21], were studied to assess 
their roles in establishing uterine receptivity in vitro.
In our clinical samples, E2 concentration >10 nM was 
associated with significantly decreased levels of integrin 
Fig. 2 E2 enhanced the expression and distribution of integrin β3 on the plasma membranes of Ishikawa cells. a Representative image of integrin 
β1 expression as detected by western blotting. b Quantitative analysis integrin β1 expression as detected by western blotting. c Quantitative 
analysis of integrin β1 expression on the plasma membranes of Ishikawa cells as detected by flow cytometry. d Representative image of integrin β3 
expression as detected by western blotting. e Quantitative analysis integrin β3 expression as detected by western blotting. f Quantitative analysis 
of integrin β3 distribution on the plasma membranes of Ishikawa cells as detected by flow cytometry. Double asterisk indicates significantly different 
from the control group, P < 0.01
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β3 expression. Based on our clinical investigations, the 
physiological concentrations of E2 range from 0.1 to 
0.3  nM, and increase to ~3  nM during premenstrual 
and menstrual cycles. As previous in  vitro studies have 
reported that a 10 nM E2 concentration had the strongest 
effect for inducing ERK1/2 and Akt phosphorylation [18], 
we selected the10 nM E2 concentration as our threshold 
for classifying clinical samples. Our investigations with 
clinical samples indicated that E2 concentrations >10 nM 
was associated with significantly decreased levels of inte-
grin β1 expression. Our grouping strategy based on this 
criterion provided evidence that alterations in the E2 to 
P4 level had a marked influence on integrin expression. 
This effect might be related to a previous finding that 
only E2 concentrations >10 nM produced toxic effects in 
cells [18]. This idea had been further verified in a previ-
ous study in which 10 nM was shown to be the threshold 
concentration of E2 at which its positive effect on ovula-
tion induction changed to a negative effect [22]. Moreo-
ver, findings in our current study also partially support 
this hypothesis. For example, our western blot studies 
showed no significant difference in integrin β3 expression 
when the E2 concentration was <10 nM (data not shown), 
while a 100 nM E2 concentration dramatically decreased 
integrin β3 distribution on plasma membrane when com-
pared with a control E2 concentration.
The expression level of integrin and its plasma mem-
brane distribution are one of the positive biomark-
ers of uterine receptivity [21]. In the present study, 
we screened the expression of integrins which were 
reported positive expression in human uterus. The 
expression level of integrin β1 and integrin β3 were 
regulated by blood E2 and P4 levels. Integrin β1 is 
constitutively expressed during the menstrual cycle 
and may be involved in the re-establishment of epi-
thelialization following menstruation. Integrin β3 is 
expressed on a weekly basis by epithelial cells in pro-
liferative endometrium; decreased endometrial expres-
sion of integrin β3 accompanied by reduced uterine 
receptivity has been verified in several pathological 
conditions [23]. Thus, the two indicators clearly reflect 
the effects of E2 and P4 on the establishment of uterine 
Fig. 3 P4 enhanced the expression of integrin β1 and its distribution on the plasma membranes of Ishikawa cells. a Representative image of integ-
rin β1 expression as detected by western blotting. b Quantitative analysis of integrin β1 expression as detected by western blotting. c Quantitative 
analysis of integrin β1 distribution on the plasma membranes of Ishikawa cells as detected by flow cytometry. d Representative image of integrin 
β3 expression as detected by western blotting. e Quantitative analysis of integrin β3 expression as detected by western blotting. f Quantitative 
analysis of integrin β3 distribution on the plasma membranes of Ishikawa cells as detected by flow cytometry. Double asterisk indicates significantly 
different from the control group, P < 0.01
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receptivity. In addition to determining how the E2 to 
P4 ratio affects integrin markers in clinical samples, 
we also established in  vitro cell models for assessing 
the respective effects of E2 and P4 on integrin β3 and 
β1 expression and embryo attachment efficiency. Our 
in  vitro results showed that 100  nM E2 significantly 
suppressed the production and distribution of inte-
grin β3, while 100  nM P4 significantly enhanced the 
expression and surface distribution of integrin β1 and 
rescued the efficiency of embryo attachment inhibited 
by 100 nM E2. These results are indicative of the spe-
cific effect of each of these two hormones on different 
integrin members, suggest that is reasonable to con-
catenately use integrins β1 and β3 expression level and 
blood E2 and P4 level as biological markers for pre-
dicting uterine receptivity.
In addition to investigating how E2 and P4 levels respond 
to the respective functions of these two hormones, we also 
investigated the effects of treatment with different combi-
nations of E2 and P4 concentrations. Our results showed 
that P4 attenuated the negative regulatory effect of E2 on 
integrin β3. It is known that P4 can inhibit the prolifera-
tive effect of E2 on endometrium by down-regulating the 
expression of E2 receptors [24]. While this antagonistic 
effect of P4 on E2 is generally believed to influence the 
completeness of the secretory transformation of endo-
metrium [20]; during the embryo implantation process, a 
high E2 level will cause the window of uterine receptivity 
to rapidly close [1]. When considering the determinant 
role of E2 in specifying the duration of uterine receptivity 
for implantation, the use of P4 to regulate E2 levels might 
be justified as a method for improving IVF and ET results.
Fig. 4 P4 eliminated E2-induced reductions in the expression and plasma membrane distribution of integrin β3 in Ishikawa cells. a Representative 
image of integrin β1 expression as detected by western blotting. b Quantitative analysis of integrin β1 expression as detected by western blotting. 
c Quantitative analysis of integrin β1 expression on the plasma membranes of Ishikawa cells as detected by flow cytometry. d Representative 
image of integrin β3 expression as detected by western blotting. e Quantitative analysis of integrin β3 expression as detected by western blotting. f 
Quantitative analysis of integrin β3 distribution on the plasma membranes of Ishikawa cells as detected by flow cytometry. Double asterisk indicates 
significantly different in three separate assays, P < 0.01
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Conclusions
In summary, our major finding was that increased E2 
levels inhibited embryo implantation because they 
decreased the expression pattern of integrin β3. P4 
markedly altered the expression pattern of integrin β1, 
and allowed it to rescue integrin β3 functions in the 
uterus. Because E2 and P4 appear to regulate the expres-
sion patterns of different integrins in specific manners, 
and when considering the respective functions of the 
two hormones, we recommend that any assessment of 
uterine receptivity should take the concatenate status of 
multiple biomarkers into consideration. We also hypoth-
esize that antagonizing E2 by administration of P4 might 
be utilized as a method for improving the outcomes of 
techniques such as IVF and ET. Additional comprehen-
sive studies regarding the E2-P4 balance and its effects 
on integrin family members will be performed to test 
our hypothesis.
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